

In the Claims

1. (currently amended) ~~Use of~~ A method of decreasing or inhibiting hyperproliferation of keratinocytes and/or T-cells comprising administering an effective amount of a medicament comprising Riluzole or a pharmaceutically acceptable salt thereof if desired with appropriate adjuvants and additives for the production of a medicament for the therapy or prevention of a diseased characterized to a subject in need of inhibition of hyperproliferation of keratinocytes and/or T-cells, whereby hyperproliferation of keratinocytes and/or T cells is decreased or inhibited.

2. (currently amended) ~~Use~~ The method according to claim 1, ~~characterized in that the wherein the subject has a disease is~~ selected from the group consisting of psoriasis, atopic dermatitis, actinic keratosis, hyperkeratosis like epidermolytic hyperkeratosis, hyperkeratosis lenticularis perstans, keratosis pilaris and ichthyoses.

3. (currently amended) The method ~~Use~~ according to claim 1, wherein the subject has ~~a~~ characterized in that the disease is selected from the group consisting of alopecia areata, alopecia totalis, alopecia subtotalis, alopecia universalis, alopecia diffusa, atopic dermatitis, lupus erythematoses of the skin, lichen planus, dermatomyositis of the skin, atopic eczema, atopic dermatitis morphea, scleroderma, psoriasis vulgaris, psoriasis capitis, psoriasis guttata, psoriasis inversa, alopecia areata Ophiasis type, androgenic alopecia, allergic contact dermatitis, irritative contact dermatitis, contact dermatitis, pemphigus vulgaris, pemphigus foliaceus, pemphigus vegetans, scarring mucous membrane pemphigoid, bullous pemphigoid, mucous membrane pemphigoid, dermatitis, dermatitis herpetiformis Dühring, urticaria, necrobiosis lipoidica, erythema nodosum, lichen vidal, prurigo simplex, prurigo nodularis, prurigo acuta, linear IgA dermatosis, polymorphic light dermatosis, erythema solaris, lichen sclerosus et atrophicans, exanthema of the skin, drug exanthema, purpura chronica progressiva, dihidrotic eczema, eczema, fixed drug exanthema, photoallergic skin reaction, lichen simplex periorale dermatitis, graft-versus-host-disease, acne, abnormal scarring keloids and vitiligo.

4. (currently amended) ~~Use~~ The method according to ~~one of claims 1 to 3~~ claim 1, ~~characterized in that~~ wherein the medicament is applied topically.

5. (currently amended) ~~Use~~ The method according to claim 4, ~~characterized in that~~ wherein the medicament is formulated in the form of an ointment, a gel, a band-aid, an emulsion, a lotion, a foam, a cream of a mixed phase or an amphiphilic emulsion system (oil/water-water/oil-mixed phase), a liposome, a transferosome, a paste or a powder.

6. (currently amended) ~~Use~~ The method according to claim 5, ~~characterized in that~~ wherein the cream is cream basis ~~DAC~~ (Deutscher Arzneimittel Codex (DAC) Basiscreme).

7. (currently amended) ~~Use~~ The method according to ~~one of claims 1 to 6~~ claim 1, ~~characterized in that~~ wherein the medicament comprises Riluzole or a pharmaceutically acceptable salt thereof ~~is comprised within the medicament~~ in a concentration based on the weight of the total formulation of between 0.01%-10% Riluzole, preferably between 0.1%-8% Riluzole, even more preferred between 1% and 4% Riluzole.

8. (currently amended) ~~Use~~ The method according to ~~one of claims 1 to 7~~ claim 1, ~~characterized in that~~ wherein the medicament comprises Riluzole or a pharmaceutically acceptable salt thereof ~~is comprised within the medicament~~ in a concentration of between 1 μ mol/l and 100 mmol/l.

9. (currently amended) ~~Composition~~ A composition comprising Riluzole or a pharmaceutically acceptably salt thereof and one or more additional active ingredients, which decrease or inhibit the hyperproliferation of keratinocytes and/or T cells.

10. (currently amended) ~~Composition~~ A composition according to claim 79, characterized in that the additional active ingredient is selected from the group consisting of vitamin D derivatives, as

agonists of vitamin D receptors, ~~in particular~~ Calcipotriol, retinoid derivatives as agonists of retinoid receptors (RAR), ~~in particular~~ tazarotene, corticosteroid derivatives of glucocorticoid receptors, ~~in particular~~ betamethasone, and cortisone, fumaric acid, skin thinning agents, ~~in particular~~ clobetasol, antagonists of TNF alpha, antagonists of dihydrofolate-dehydrogenase, ~~in particular~~ methotrexate, and immunosuppressive substances like, for example, amphotericin, busulfan, cotrimoxazole, chlorambucil, colony stimulating factor, cyclophosphamide, fluconazole, ganciclovir, anti-lymphocyte immunoglobulins, regular immunoglobulins, methylprednisolone, octreotide, oxpentifylline, thalidomide, zolimomab aritox and clotrimazole.

11. (currently amended) ~~Composition~~ A composition comprising Riluzole or a pharmaceutically acceptable salt thereof and one or more calcineurin antagonist(s)s.

12. (currently amended) ~~Composition~~ A composition according to claim 911, wherein the calcineurin antagonist is selected from the group consisting of cyclosporine A, cyclosporine G, cyclosporine B, cyclosporine C, cyclosporine D, dihydro-cyclosporine D, Cyclosporine E, cyclosporine F, cyclosporine H, cyclosporine I, ASM-240, pimecrolimus, tacrolimus, 13-desmethyl derivatives of tacrolimus and/or 17-ethyl-derivatives of tacrolimus.

13. (Cancelled).

14. (currently amended) ~~Topical~~ A topical medicament for transdermal delivery comprising Riluzole or a pharmaceutically acceptable salt thereof and a topical excipient, ~~characterized in that~~ wherein no significant amount of a dermal penetration enhancer is present in the medicament.

15. (currently amended) ~~Topical~~ A topical medicament ~~for transdermal delivery, characterized in that~~ according to claim 14, wherein the topical excipient is selected from the group consisting of an emulsion, a gel, an ointment, a foam, a band-aid, a cream of a mixed-phase and amphiphilic, respectively emulsion system (oil/water-water/oil-mixed-phase), a liposome or transfersome.

16. (currently amended) ~~Topical~~ A topical medicament according to claim 14 ~~or 15~~, characterized in that wherein the topical excipient is cream basis DAC. .

17. (currently amended) ~~Topical~~ A topical medicament according to ~~claims 14 to 16~~ claim 14, characterized in that wherein the Riluzole or a pharmaceutically acceptable salt thereof is ~~comprised within the medicament~~ present based on the weight of the total formulation in a concentration of between 0.01%-10% Riluzole, preferably between 0.1%-8% Riluzole, ~~even more preferred between 1% and 4% Riluzole.~~

18. (currently amended) ~~Topical~~ A topical medicament according to ~~claims 14 to 17~~ claim 14, characterized in that wherein the medicament further comprises a compound selected from the group consisting of selegiline; selegiline in combination with tocopherol; levodopa; bromocriptine; bromocriptine; trihexyphenidyl; trihexyphenidyl; amantadine; botulinum toxin type A; tizanidine; dantrolene sodium; baclofen; benzodiazepines; preferably diazepam or clonazepam; clonidine; gabapentin; lamotrigine; cyproheptadine; cannabinoid-like compounds; fluoxetine; paroxetine; sertraline; fluvoxamine; citalopram; escitalopram; St. John's wort; enlafaxine; bupropion; nefazodone; mirtazapine; trazodone; tricyclic antidepressants; preferably amitriptyline; nortriptyline; desipramine; clomipramine; doxepin; protriptyline; trimipramine; or imipramine; MAO-inhibitors; preferably phenelzine or tranylcypromine; anticholinergic agents, preferably benztropine; procyclidine; diphenhydramine; clozapine; olanzapine; risperidone; quetiapine; ziprasidone; topiramate; tiagabine; oxacarbazepine; phenytoin; carbamazepine; fosphenytoin; zonisamide; clobazam; clonazepam; phenobarbital; primidone; vigabatrin; valproate; felbamate; levetiracetam; barbiturates; imidazopyridine; antihistamines; preferably doxylamine; piperidines; preferably glutethimide or methypyrlyon; ethchlorvynol; chloral derivatives; preferably chloral hydrate, and carbamates, preferably and meprobamate.

19. (currently amended) ~~Use of~~ A method of administering Riluzole or a pharmaceutically acceptable salt thereof ~~for the preparation of a topical medicament~~ to a subject in need of treatment

for the therapy and/or prevention of neuronal or brain diseases and/or injuries, the method comprising applying a topical medicament comprising Riluzole or a pharmaceutically acceptable salt thereof, whereby Riluzole or a pharmaceutically acceptable salt thereof is administered.

20. (currently amended) ~~Use~~ The method according to claim 1819, characterized in that ~~wherein the neuronal or brain diseases-disease and/or injuries-injury is selected from the group consisting of Parkinson's disease, adrenoleukodystrophy, Dyskenesias, motoneuron diseases like spinal muscular atrophy, and infantile muscular atrophy, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis, for disease states where anticonvulsant, anxiolytic or hypnotic activity is needed, schizophrenia, sleep disorders and depression, cerebrovascular disorders and suppressing pain, spinal, cranial or craniospinal traumas, damages by radiation, parkinsonian syndrome, neuro-AIDS, mitochondrial diseases, cerebellar dysfunction, acoustic traumas, especially deafness and tinnitus, spasticity, especially pyramidal spasticity, and reduction of spinal cord injury induced by aortic cross-clamping.~~

21. (currently amended) ~~Use of Riluzole or a pharmaceutical acceptable salt thereof and~~ The method of claim 3, wherein the medicament comprises cream basis DAC for the preparation of a topical medicament for the treatment and/or prevention of skin disorders, especially psoriasis, atopic dermatitis, alopecia areata, alopecia totalis, alopecia subtotalis, alopecia universalis, alopecia diffusa, lupus erythematoses of the skin, lichen planus, dermatomyositis of the skin, atopic eczema, morphea, skleroderma, psoriasis vulgaris, psoriasis capitis, psoriasis guttata, psoriasis inversa, alopecia areata ophioid type, androgenetic alopecia, allergic contact eczema, irritative contact eczema, contact eczema, pemphigus vulgaris, pemphigus foliaceus, pemphigus vegetans, scarring mucosal pemphigoid, bullous pemphigoid, mucous pemphigoid, dermatitis, dermatitis herpetiformis duhring, urticaria, necrobiosis lipoidica, erythema nodosum, lichen vidal, prurigo simplex, prurigo nodularis, prurigo acuta, linear IgA dermatosis, polymorphic light dermatoses, erythema solaris, lichen sclerosus et atrophicus, exanthema of the skin, drug exanthema, purpura chronica progressiva, dihidrotic eczema, Eczema, fixed drug exanthema, photoallergic skin reaction, lichen simplex

~~erionale, dermatitis, "Graft versus Host Disease", acne, rosacea, abnormal scarring, keloids and vitiligo.~~

22. (Cancelled).

23. (New) The method of claim 2, wherein the medicament comprises cream basis DAC.